AGIO - Agios Pharmaceuticals Inc Stock Price, Fair Value and News

48.06USD-0.44 (-0.91%)Market Closed

Market Summary

USD48.06-0.44

Market Closed

-0.91%

AGIO Alerts

1 major insider sales recently.

AGIO Stock Price

View Fullscreen

AGIO RSI Chart

AGIO Valuation

Market Cap

2.7B

Price/Earnings (Trailing)

-7.74

Price/Sales (Trailing)

90.43

EV/EBITDA

-7.27

Price/Free Cashflow

-9.05

AGIO Price/Sales (Trailing)

AGIO Profitability

EBT Margin

-1166.86%

Return on Equity

-47.4%

Return on Assets

-41.5%

Free Cashflow Yield

-11.05%

AGIO Fundamentals

AGIO Revenue

Revenue (TTM)

30.2M

Rev. Growth (Yr)

-18.85%

Rev. Growth (Qtr)

-31.19%

AGIO Earnings

Earnings (TTM)

-352.6M

Earnings Growth (Yr)

-0.66%

Earnings Growth (Qtr)

15%

Breaking Down AGIO Revenue

Last 7 days

3.1%

Last 30 days

10.8%

Last 90 days

52.6%

Trailing 12 Months

87.7%

How does AGIO drawdown profile look like?

AGIO Financial Health

Current Ratio

12.84

AGIO Investor Care

Shares Dilution (1Y)

2.14%

Diluted EPS (TTM)

-6.31

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	30.2M	0	0	0
2023	17.2M	23.7M	27.5M	27.6M
2022	85.0M	45.6M	6.3M	12.3M
2021	0	163.8M	124.4M	0
2020	174.8M	184.3M	193.7M	203.2M
2019	115.9M	101.7M	112.5M	117.9M
2018	41.3M	70.3M	74.2M	94.4M
2017	49.1M	53.5M	55.9M	43.0M
2016	70.7M	64.5M	68.0M	69.9M
2015	62.0M	66.9M	38.4M	44.6M
2014	27.7M	29.8M	57.5M	65.4M
2013	25.1M	25.1M	25.1M	25.5M
2012	22.7M	23.5M	24.3M	25.1M
2011	0	0	0	21.8M

Get all data in R, Python etc through our Historical Stock Data APIs

About Agios Pharmaceuticals Inc

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism. The company develops PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias; and AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

CEO	Mr. Brian M. Goff M.B.A.
WEBSITE	agios.com
INDUSTRY	Biotechnology
EMPLOYEES	389

Agios Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Agios Pharmaceuticals Inc? What does AGIO stand for in stocks?

AGIO is the stock ticker symbol of Agios Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Agios Pharmaceuticals Inc (AGIO)?

As of Fri Jul 26 2024, market cap of Agios Pharmaceuticals Inc is 2.73 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AGIO stock?

You can check AGIO's fair value in chart for subscribers.

Is Agios Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether AGIO is over valued or under valued. Whether Agios Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Agios Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AGIO.

What is Agios Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jul 26 2024, AGIO's PE ratio (Price to Earnings) is -7.74 and Price to Sales (PS) ratio is 90.43. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AGIO PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Agios Pharmaceuticals Inc's stock?

In the past 10 years, Agios Pharmaceuticals Inc has provided 0.019 (multiply by 100 for percentage) rate of return.